Latest Information Update: 18 Oct 2007
At a glance
- Originator Chiesi Farmaceutici
- Class Antiasthmatics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 31 Dec 2003 Phase-I clinical trials in Asthma in Italy (unspecified route)
- 25 Feb 2003 Preclinical trials in Asthma in Italy (unspecified route)